Cytek Overview
- Year Founded
-
1992

- Status
-
Public
- Employees
-
645

- Stock Symbol
-
CTKB

- Investments
-
4
- Share Price
-
$5.23
- (As of Friday Closing)
Cytek General Information
Description
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Contact Information
Website
www.cytekbio.comCorporate Office
- 47215 Lakeview Boulevard
- Fremont, CA 94538-6407
- United States
Corporate Office
- 47215 Lakeview Boulevard
- Fremont, CA 94538-6407
- United States
Cytek Stock Performance
As of 14-Feb-2025, Cytek’s stock price is $5.23. Its current market cap is $674M with 129M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$5.23 | $5.22 | $4.66 - $9.33 | $674M | 129M | 708K | -$0.08 |
Cytek Financials Summary
As of 30-Sep-2024, Cytek has a trailing 12-month revenue of $201M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 465,106 | 963,489 | 1,051,131 | 1,805,951 |
Revenue | 201,210 | 193,015 | 164,036 | 127,950 |
EBITDA | (6,306) | (10,821) | 4,873 | 8,872 |
Net Income | (10,160) | (12,148) | 2,576 | 3,001 |
Total Assets | 491,226 | 494,457 | 519,476 | 463,305 |
Total Debt | 14,518 | 14,136 | 18,094 | 0 |
Cytek Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Cytek Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Cytek Comparisons
Industry
Financing
Details
Cytek Competitors (4)
One of Cytek’s 4 competitors is Imperial Life Sciences, a Corporation company based in Gurugram, India.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Imperial Life Sciences | Corporation | Gurugram, India | ||||
FluoroFinder | Venture Capital-Backed | Broomfield, CO | ||||
Active Motif | Private Equity-Backed | Carlsbad, CA | ||||
Treefrog Therapeutics | Venture Capital-Backed | Pessac, France |
Cytek Patents
Cytek Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20250020639-A1 | Ultra-bright nanoparticle fluorescent dye complexes | Pending | 18-Jun-2023 | ||
US-20240210397-A1 | High parameter flow cytometric assay to identify human myeloid derived suppressive cells | Pending | 14-Dec-2022 | ||
US-20240159757-A1 | High parameter 20 color panel for effective detection of aberrant cells in acute myeloid leukemia | Pending | 20-Oct-2022 | ||
US-20240226872-A9 | Removable circular nozzle for flow cytometers | Pending | 20-Oct-2022 | ||
US-20240131506-A1 | Removable circular nozzle for flow cytometers | Pending | 20-Oct-2022 | B01L3/502 |
Cytek Signals
Cytek Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Cytek Acquisitions (4)
Cytek’s most recent deal was a Merger/Acquisition with Luminex (Flow Cytometry & Imaging Business) for . The deal was made on 28-Feb-2023.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Luminex (Flow Cytometry & Imaging Business) | 28-Feb-2023 | Merger/Acquisition | Biotechnology | ||
Merck (Flow Cytometry Unit) | 28-Feb-2023 | Merger/Acquisition | Pharmaceuticals | ||
Tonbo Biosciences | 02-Nov-2021 | Merger/Acquisition | Biotechnology | ||
Cytoville | Merger of Equals | Other Devices and Supplies |
Cytek ESG
Risk Overview
Risk Rating
Updated June, 07, 2023
29.05 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Healthcare
Industry
of 587
Rank
Percentile

Medical Devices
Subindustry
of 199
Rank
Percentile

Cytek FAQs
-
When was Cytek founded?
Cytek was founded in 1992.
-
Where is Cytek headquartered?
Cytek is headquartered in Fremont, CA.
-
What is the size of Cytek?
Cytek has 645 total employees.
-
What industry is Cytek in?
Cytek’s primary industry is Other Devices and Supplies.
-
Is Cytek a private or public company?
Cytek is a Public company.
-
What is Cytek’s stock symbol?
The ticker symbol for Cytek is CTKB.
-
What is the current stock price of Cytek?
As of 14-Feb-2025 the stock price of Cytek is $5.23.
-
What is the current market cap of Cytek?
The current market capitalization of Cytek is $674M.
-
What is Cytek’s current revenue?
The trailing twelve month revenue for Cytek is $201M.
-
Who are Cytek’s competitors?
Imperial Life Sciences, FluoroFinder, Active Motif, and Treefrog Therapeutics are competitors of Cytek.
-
What is Cytek’s annual earnings per share (EPS)?
Cytek’s EPS for 12 months was -$0.08.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »